Skip to main content

Advertisement

SpringerLink
Log in

Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Currently, there is no effective single antigen and there are only a very limited number of complex antigens for the diagnosis of early-stage breast cancer (BC). In this study, we used serological analysis of recombinant cDNA expression libraries (SEREX) in combination with phage display technology to screen complex autoantigens from the sera of BC patients. The cDNA expression library was constructed using tissue samples of three patients with BC at as early as stage T1N0M0. The serum samples of ten patients, including the three patients who provided tissue samples, as well as five healthy human subjects as controls were used to screen the library. All seven autoantigens were identified from the library by four rounds of screening and matched the existing genes after a blast search using NCBI-BLAST. Then, the expression conditions of the autoantibodies of the seven autoantigens and anti-CA15-3 in the sera from 100 BC patients and 50 healthy donors were examined by gray values. The data were analyzed by the area under the receiver operating characteristic (ROC) curve and logistic regression diagnostic models. In the end, a panel of complex autoantigens consisting of B11 (LGALS3), B18 (PHB2), B119 (MUC1), B130 (GK2), and CA15-3, which had a sensitivity of 87 % and a specificity of 76 %, were identified. The area under the curve (AUC) of the complex antigens was 0.872, which is significantly greater than that of anti-CA15-3 alone (AUC = 0.634) for the diagnosis of BC. Thus, this panel of complex antigens provides a promising strategy for the diagnosis of early-stage BC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Chourb S, Mackness BC, Farris LR, McDonald MJ. Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health. 2011;3:1949–4998.

    Article  Google Scholar 

  2. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. International journal of proteomics 2011, 2011.

  3. Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.

    CAS  PubMed  Google Scholar 

  4. Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dong X, Yang M, Sun H, Lu J, Zheng Z, Li Z, et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther. 2013;6:273–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Al-Salam S, Al-Salam M, Al AM. Galectin-3: a novel protein in cerebellar hemangioblastoma. Int J Clin Exp Pathol. 2013;6:853–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013;44:2400–9.

    Article  CAS  PubMed  Google Scholar 

  10. Dawson H, Andre S, Karamitopoulou E, Zlobec I, Gabius HJ. The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res. 2013;33:3053–9.

    CAS  PubMed  Google Scholar 

  11. Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer. 2011;117:4375–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lee MH, Lin L, Equilibrina I, Uchiyama S, Matsunaga S, Fukui K. ASURA (PHB2) is required for kinetochore assembly and subsequent chromosome congression. Acta Histochem Cytochem. 2011;44:247–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sievers C, Billig G, Gottschalk K, Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE. 2010;5:e12735.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J Thromb Haemost. 2012;10:411–8.

    Article  CAS  PubMed  Google Scholar 

  15. Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. MolCarcinog 2013.

  16. Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, First Affiliated Hospital of Xi’an Jiaotong University Medical College, 277 Yanta West Road, Xi’an, Shaanxi Province, 710061, People’s Republic of China

    Xiaoxiao Zuo, Ling Chen, Lifeng Liu, Xiaojin Zhang, Qing Yu, Lu Feng, Xinhan Zhao & Tianjie Qin

  2. Department of Traditional Chinese Medicine, First Affiliated Hospital of Xi’an Jiaotong University Medical College, Xi’an, Shaanxi Province, 710061, People’s Republic of China

    Zhe Zhang

Authors
  1. Xiaoxiao Zuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lifeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhe Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaojin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qing Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lu Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xinhan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tianjie Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xinhan Zhao or Tianjie Qin.

Additional information

Xiaoxiao Zuo and Ling Chen contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zuo, X., Chen, L., Liu, L. et al. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer. Tumor Biol. 37, 1309–1317 (2016). https://doi.org/10.1007/s13277-015-3932-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3932-y

Keywords

Search

Navigation